Market context for this story
Loading quotes…
Informational only — not investment advice. Full markets →
Barry, OppHub America Desk · · Source: investing-com-stocks
Alkermes Stock $ALKS Dip: Q2 Earnings Beat, Guidance Dissatisfies Wall Street
💡 U.S. investors should monitor $ALKS for potential volatility as the company navigates guidance adjustments and integrates its new acquisition.,Observe analyst reactions and revised price targets to gauge long-term sentiment, particularly how the market values the LUMRYZ franchise contribution.,Pay attention to short interest levels and trading volume to identify further profit-taking opportunities or potential short squeezes.
$ALKSAlkermes (NASDAQ: $ALKS) shares declined following its Q2 2026 earnings report, despite surpassing revenue and adjusted EPS expectations. The drop was largely attributed to the company's reaffirmed full-year revenue guidance midpoint falling below analyst forecasts, signaling investor concern after a significant year-to-date rally.
Shares of Alkermes, Inc. (NASDAQ: $ALKS) saw a pre-market dip of 5.2% to $50.00 following the release of its second-quarter 2026 financial results. While the pharmaceutical company reported an adjusted earnings per share of $0.00, exceeding the -$0.02 consensus, and revenue of $496 million, above the $459 million forecast and a 27% year-over-year increase, these positive figures were overshadowed by an outlook that fell short of Wall Street's expectations.
The primary driver of the investor disappointment was Alkermes' reaffirmed full-year 2026 revenue guidance midpoint of $1.785 billion, which landed below the analyst consensus of $1.81 billion. This gap proved sufficient to trigger profit-taking, particularly as the stock had surged approximately 88% year-to-date and faced considerable short interest, accounting for roughly 10.7% of its float.
Despite the immediate sell-off, some analysts remain optimistic. Piper Sandler, for instance, raised its price target for Alkermes from $43 to $65 and maintained an Overweight rating, citing the company's undervaluation. However, this positive analyst sentiment was insufficient to halt the pre-market decline. The company's narcolepsy treatment, LUMRYZ, acquired through the recent $2.4 billion purchase of Avadel Pharmaceuticals, played a significant role in the revenue beat, although integration costs and the tempered guidance appear to be affecting overall investor sentiment. The broader market saw mixed performance, with the Nasdaq pressured while the S&P 500 and Dow Jones posted slight gains, indicating the decline in $ALKS was company-specific rather than a market-wide trend.
Based on reporting from investing-com-stocks.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →Curated tools and reads — shopping here helps keep OppHub America free.
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: July 28, 2026 at 9:28 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biotech earnings and guidance
Alkermes made more money than expected this quarter, but its future sales forecast disappointed Wall Street. Investors who had already enjoyed big gains earlier in the year decided to cash out and sell some shares.
What changed
Alkermes reported strong Q2 earnings and revenue beats but reaffirmed a full-year revenue guidance midpoint that fell below analyst expectations.
Who wins / who loses
Short-term profit-takers and bearish traders benefit from the dip, while long-term growth investors face near-term volatility despite positive analyst price targets.
Time horizon
Think in terms of the next few weeks.
Confidence & best fit
medium confidence · Long-term investor, Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $ALKSWatch — track, don’t rush
The main company in the story saw its stock price drop because investors wanted higher future sales forecasts.
View $ALKS chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Options are too risky here because the stock could bounce or drop further based on news; beginners should skip them.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research competing narcolepsy treatment providers and acquisition targets in the specialty pharma space.
What would break this thesis
- An unexpected upward revision in guidance or major positive clinical trial data from the LUMRYZ pipeline.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.